skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Datamonitor Healthcare explores the rationale behind AbbVie’s agreed $54bn acquisition of Shire.

 

Tax inversion – Re-domiciling in the UK to lower tax burden and improve access to global cash flows.

Portfolio diversification – Diluting Humira dependence with new rare diseases unit and strong pipeline growth

Highlights from the whitepaper include:

Tax inversion – Re-domiciling in the UK to lower tax burden and improve access to global cash flows.

Portfolio diversification- Diluting Humira dependence with new rare diseases unit and strong pipeline growth


AbbVie-Shire-Whitepaper

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888-670-8900
  • US Toll           : +1 908-547-2200
  • UK & Europe : +44 (20) 337 73737
  • Australia       : +61 2 8705 6907
  • Japan            : +81 3-6273-4257

Or email us your inquiry, so we can provide you the best possible customer service:
pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: